01.02.2010 • NewsBayerinvestmentLeverkusen

Bayer MaterialScience:World’s Largest Carbon Nanotube Pilot Facility

Bayer MaterialScience has opened a new pilot facility for the manufacture of carbon nanotubes (CNTs) at Chempark Leverkusen (Germany). The company has invested some €22 million in the planning, development and construction of the facility, which is the largest of its kind in the world and has an annual capacity of 200 metric tons.

By investing in one of the key technologies of the future, Bayer MaterialScience is looking to gain a head start in supplying the demand for a whole host of applications for multi-wall carbon nanotubes, which the company is marketing under the trade name Baytubes.

"Current forecasts predict an annual growth rate of 25% percent for carbon nanotubes. Within 10 years, the market is expected to be worth $2 billion," said Dr. Joachim Wolff, a member of Bayer MaterialScience's executive committee and head of the Coatings, Adhesives, Specialties segment. "We are also expecting nanotechnology to create a total of 100,000 new jobs in the German industry in the medium term."

Company

Logo:

Covestro


51368 Leverkusen
Germany

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.